Geron (GERN) Competitors

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Geron (NASDAQ:GERN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk, community ranking and institutional ownership.

Is MDGL or GERN more profitable?

Madrigal Pharmaceuticals has a net margin of 0.00% compared to Geron's net margin of -682.48%. Geron's return on equity of -67.53% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%
Geron	-682.48%	-67.53%	-45.46%

Do institutionals and insiders have more ownership in MDGL or GERN?

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more volatility and risk, MDGL or GERN?

Madrigal Pharmaceuticals has a beta of -0.36, suggesting that its share price is 136% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Which has better earnings and valuation, MDGL or GERN?

Geron has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	N/A	N/A	-$373.63M	-$25.08	-11.71
Geron	$240K	7,279.19	-$184.13M	-$0.32	-9.03

Does the media favor MDGL or GERN?

In the previous week, Madrigal Pharmaceuticals had 19 more articles in the media than Geron. MarketBeat recorded 26 mentions for Madrigal Pharmaceuticals and 7 mentions for Geron. Geron's average media sentiment score of 0.86 beat Madrigal Pharmaceuticals' score of 0.49 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor MDGL or GERN?

Geron received 35 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.07% of users gave Geron an outperform vote while only 67.80% of users gave Madrigal Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Madrigal Pharmaceuticals	Outperform Votes 459 67.80%	Underperform Votes 218 32.20%
Geron	Outperform Votes 494 70.07%	Underperform Votes 211 29.93%

Do analysts recommend MDGL or GERN?

Madrigal Pharmaceuticals currently has a consensus price target of $351.67, indicating a potential upside of 19.76%. Geron has a consensus price target of $7.25, indicating a potential upside of 150.87%. Given Geron's stronger consensus rating and higher possible upside, analysts plainly believe Geron is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Geron	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.09

Summary

Geron beats Madrigal Pharmaceuticals on 13 of the 18 factors compared between the two stocks.